RELV - Reliv' International, Inc.
| Previous Close | 3.4900 |
| Open | 3.4500 |
| Bid | 3.4000 x 900 |
| Ask | 5.4300 x 1000 |
| Day's Range | 3.3772 - 3.4900 |
| 52 Week Range | 3.3200 - 7.7500 |
| Volume | 2,993 |
| Avg. Volume | 30,339 |
| Market Cap | 6.179M |
| Beta (5Y Monthly) | 0.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0440 |
| Earnings Date | Mar 26, 2020 - Mar 30, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Nov 12, 2013 |
| 1y Target Est | 21.00 |
- PR Newswire
Reliv International Reports Third-Quarter Financial Results for 2019
CHESTERFIELD, Mo. , Nov. 14, 2019 /PRNewswire/ -- Reliv International, Inc. (NASDAQ:RELV), a marketer of nutritional supplements that promote optimal health, today reported its financial results for the ...
- Simply Wall St.
Is Reliv' International (NASDAQ:RELV) Using Debt Sensibly?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
- PR Newswire
Reliv International Reports Second-Quarter Financial Results for 2019
CHESTERFIELD, Mo. , Aug. 9, 2019 /PRNewswire/ -- Reliv International, Inc. (NASDAQ:RELV), a maker of nutritional supplements that promote optimal health, today reported its financial results for the second ...
- PR Newswire
Dr. Alfredo Galvez Appointed as Reliv International's Chief Scientific Advisor
CHESTERFIELD, Mo., Aug. 7, 2019 /PRNewswire/ -- Reliv International, a 30-year-old wellness company located in Chesterfield, MO, announced today that Dr. Alfredo Galvez has been appointed as the company's Chief Scientific Advisor. Galvez has been associated with Reliv since 2013 and is best known for his groundbreaking work with lunasin, a naturally occurring soy peptide. Through scientific research and clinical trials, Galvez has proven that lunasin affects gene expression and is the first dietary ingredient shown to promote optimal health at the epigenetic level. Galvez serendipitously discovered the soy peptide in 1996 as a postdoctoral researcher at UC Berkeley. He has a PhD in Genetics from UC Davis, majoring in molecular biology and cytogenetics. After completing his PhD, Galvez worked for the USDA-ARS at Washington State University and at the University of California Berkeley as a Research Biochemist and Geneticist.
- Simply Wall St.
Did Changing Sentiment Drive Reliv' International's (NASDAQ:RELV) Share Price Down By 49%?
The main aim of stock picking is to find the market-beating stocks. But in any portfolio, there will be mixed results...
- GlobeNewswire
Reliv International Reports First-Quarter Financial Results for 2019
CHESTERFIELD, Mo., May 10, 2019 -- Reliv International, Inc. (NASDAQ:RELV), a maker of nutritional supplements that promote optimal health, today reported its financial results.
- GlobeNewswire
Reliv International Reports Fourth-Quarter and Full-Year Financial Results for 2018
CHESTERFIELD, Mo., March 29, 2019 -- Reliv International, Inc. (NASDAQ:RELV), a maker of nutritional supplements that promote optimal health, today reported its financial.
